Market opportunity Target hospitals and cath labs prioritizing kidney safety and contrast reduction, leveraging Osprey’s DyeVert technology to reduce contrast-induced AKI risk and align with value-based care incentives.

Strategic partnerships Capitalize on potential collaborations with major healthcare distributors and device partners (e.g., GE Healthcare) to accelerate adoption in large networks and drive joint value propositions.

Global expansion Explore international markets where Osprey has historical activity or partnerships, including Australia and the US, to replicate success patterns and broaden revenue streams.

Clinical proof Leverage the DyeMINISH registry and ongoing real-world evidence to support compelling ROI case studies, helping to secure hospital approvals and payer interest.

Financial signals Engage growth-minded teams at mid-market to small-cap hospitals and medical device distributors with modest revenue bands, highlighting scalable deployment and initial cost savings from reduced contrast usage.